盈康生命科技股份有限公司 第六届董事会第十八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 6 月 15 日以电话、 邮件等方式向全体董事发出召开公司第六届董事会第十八次（临时）会议的通知。 会议于 2025 年 6 月 18 日在山东省青岛市崂山区海尔路一号盈康一生大厦董事会议 室以现场及通讯的方式召开。会议应出席董事 6 人，实出席董事 6 人，董事谭丽霞 以现场方式出席会议并投票表决，董事沈旭东、潘绵顺、独立董事杜媛、独立董事 姜峰、独立董事陈晓满以通讯方式出席会议并投票表决。本次会议由董事长谭丽霞 女士主持，公司的监事、高级管理人员列席了会议。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《公 司章程》及有关法律、法规的规定。 证券代码：300143 证券简称：盈康生命 公告编号：2025-026 二、董事会会议审议情况 （一）审议通过《关于修订<公司章程>的议案》 根据《中华人民共和国公司法》《上市公司章程指引》《深圳证券 ...

Group 1 - The high-pressure oxygen chamber concept declined by 2.26%, ranking among the top declines in concept sectors, with companies like Aoyang Health, International Medicine, and Weiao Co., Ltd. experiencing significant drops [1] - The main funds in the high-pressure oxygen chamber concept saw a net outflow of 363 million yuan, with seven stocks experiencing net outflows, led by Innovation Medical with a net outflow of 308 million yuan [2] - Other companies with notable net outflows include Aoyang Health, Dahu Co., Ltd., and Yinkang Life, with net outflows of 27.01 million yuan, 8.53 million yuan, and 6.79 million yuan respectively [2] Group 2 - The top gainers in concept sectors included the military equipment restructuring concept, which rose by 3.51%, and PCB concept, which increased by 3.29% [2] - The high-pressure oxygen chamber concept was among the sectors with the largest declines, alongside glyphosate and rare earth permanent magnets, which fell by 2.82% and 2.57% respectively [2] - The trading volume for the high-pressure oxygen chamber concept stocks showed varying turnover rates, with Innovation Medical at 36.76% and Aoyang Health at 17.53% [2]

Group 1 - The high-pressure oxygen chamber concept increased by 1.54%, ranking 6th among concept sectors, with five stocks rising, including Aoyang Health, which hit the daily limit, and Yingkang Life, Jinling Pharmaceutical, and International Medicine showing gains of 4.30%, 1.70%, and 0.58% respectively [1][2] - The main capital inflow into the high-pressure oxygen chamber concept was 0.52 billion yuan, with Aoyang Health receiving the highest net inflow of 68.73 million yuan, followed by Yingkang Life and Samsung Medical with net inflows of 11.24 million yuan and 9.36 million yuan respectively [2][3] - Aoyang Health, Yingkang Life, and Tiedean Heavy Industry had the highest net inflow ratios of 7.40%, 3.64%, and 3.00% respectively, indicating strong investor interest [3][4] Group 2 - The top-performing stocks in the high-pressure oxygen chamber concept included Aoyang Health with a daily increase of 10.12% and a turnover rate of 26.84%, while other notable stocks included Yingkang Life and Samsung Medical with increases of 4.30% and 0.17% respectively [3][4] - Stocks that experienced declines included Innovative Medical, Tiedean Heavy Industry, and Weiao Co., with decreases of 1.56%, 0.74%, and 0.68% respectively, indicating some volatility within the sector [1][4]

Transaction Overview - The company has approved the acquisition of 51% equity in Changsha Kexin Tumor Hospital Co., Ltd. for a total amount of RMB 357 million [1] - The valuation for the equity transfer was based on an asset evaluation report from Shanghai Dongzhou Asset Appraisal Co., Ltd. [1] Progress Update - All parties involved have confirmed the completion of pre-delivery obligations as per the equity transfer agreement [2] - The company has made the initial payment for the equity transfer to Hunan Kexin Health Industry Group Co., Ltd. [2] - The equity transfer has been officially registered, and the business license for Changsha Kexin has been updated [2] Changes in Business Registration - After the completion of the business registration change, the company now holds 51% of Changsha Kexin, making it a subsidiary included in the company's consolidated financial statements [2] - The updated shareholding structure shows the company holding 51% and Kexin Group holding 49% [2]

盈康生命科技股份有限公司 关于收购长沙珂信肿瘤医院有限公司51%股权 证券代码：300143 证券简称：盈康生命 公告编号：2025-025 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、交易概述 盈康生命科技股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开第 六届董事会第十六次会议、第六届监事会第十四次会议，审议通过了《关于收购长 沙珂信肿瘤医院有限公司 51%股权的议案》，同意公司收购长沙珂信肿瘤医院有 限公司（以下简称"长沙珂信"）51%股权（以下合称"本次交易"）。本次交易 股权转让的价格以上海东洲资产评估有限公司出具的《盈康生命科技股份有限公 司拟收购长沙珂信肿瘤医院有限公司部分股权所涉及的长沙珂信肿瘤医院有限公 司股东全部权益价值资产评估报告》（东洲评报字[2025]第 0058 号）为定价参考 依据，经交易各方协商确定，本次交易总金额为人民币 35,700 万元。具体内容详 见公司在巨潮资讯网（www.cninfo.com.cn）披露的《关于收购长沙珂信肿瘤医院有 限公司 51%股权的公告》（公告编号：20 ...

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

Financial Performance - In Q1 2025, the company achieved a revenue of 409.037 million yuan, maintaining stability [3] - Net profit attributable to shareholders was 29.993 million yuan, a year-on-year increase of 14.4% [3] - Net profit excluding non-recurring items was 29.965 million yuan, up 25.8% year-on-year [3] Business Strategy - The company focuses on the integration of traditional medical services with AI technology to enhance operational efficiency and service quality [6] - The healthcare service revenue accounted for 76.47% of total income in 2024 [6] - The company is transitioning from a traditional medical group to a technology-driven health management provider [6] Mergers and Acquisitions - The company plans to continue acquisitions, targeting profitable hospitals with a minimum of 400 beds for general hospitals or 300 beds for specialty hospitals [4] - The acquisition of Changsha Kexin is expected to enhance business scale and profitability, particularly in oncology services [8] AI Integration - The company is implementing a comprehensive AI strategy across its operations, focusing on improving diagnostic capabilities, patient experience, and operational management [4] - AI applications are structured in three layers: data infrastructure, capability components, and intelligent interaction engines [4] Operational Efficiency - In 2024, the company achieved a revenue per employee of 710,000 yuan, an increase of 8.9% year-on-year [5] - Profit per employee reached 52,600 yuan, reflecting a year-on-year growth of 20.2% [5] Care Services Development - The company is expanding its nursing and elderly care services, leveraging its existing facilities in Shanghai [3] - Plans include enhancing home care services and integrating traditional and modern medical practices [3]

证券代码：300143 证券简称：盈康生命 公告编号：2025-024 盈康生命科技股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，盈康生命科技股份有限公司（以下简称 "公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现将相 关事项公告如下： 本次集体接待日活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（http://rs.p5w.net）；或关注微信公众号（名称:全景财经）；或下载全景路演 APP，参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00—17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关注的问题与投资者进行沟通与交流，欢迎广大 投资者踊跃参与！ 特此公告。 盈康生命科技股份有限公司董事会 二〇二五年四月三十日 1 ...

Core Viewpoint - 盈康生命科技股份有限公司 continues to demonstrate steady growth in 2024, driven by its differentiated and AI-enabled strategies, enhancing operational efficiency and profitability [2][3]. Financial Performance - In Q1 2025, the company achieved revenue of 409 million yuan, a year-on-year decrease of 1.73%; net profit attributable to shareholders was 30 million yuan, an increase of 14.4%; and non-recurring net profit was also 30 million yuan, up 25.77% [2]. - For the full year 2024, the company reported revenue of 1.559 billion yuan, a year-on-year increase of 6.01%, and a net profit of 115 million yuan, up 14.92% [2]. - The compound annual growth rates for revenue and net profit over the past five years were 23.9% and 14.9%, respectively, indicating a trend of high-quality development [2]. AI Empowerment and Innovation - Since 2021, the company has strategically positioned itself in the "medical + AI" sector, establishing itself as a pioneer in group AI deployment within the industry [3]. - The company embraces a "three-full" concept of AI, focusing on full participation, full coverage, and full process, to enhance diagnostic capabilities, patient experience, and operational management [3]. - In 2024, the company reported an 8.9% increase in revenue per capita and a 20.2% increase in profit per capita, while the period expense ratio decreased by 0.8 percentage points [3]. Differentiated Development Path - The company has driven business growth through a differentiated approach, with the medical services segment generating revenue of 1.19 billion yuan in 2024, of which tumor-related revenue was 380 million yuan, accounting for 31.9% of medical service revenue, an increase of 17% year-on-year [4]. - The company has developed a "three-special" system focusing on specialized departments, diseases, and expertise, integrating medical innovation to enhance user experience and meet diverse needs [4]. External Growth Strategy - In 2025, the company plans to deepen its tumor medical specialty through external growth, announcing a cash acquisition of 51% of Changsha Kexin Tumor Hospital for 357 million yuan [6]. - Changsha Kexin, established in 2015, is a tertiary tumor specialty hospital with 420 beds and advanced radiotherapy equipment, performing over 8,000 minimally invasive surgeries annually [6]. - The acquisition is part of the company's strategy to enhance its regional medical center layout and is expected to significantly improve its technical depth and service breadth in the tumor specialty field, thereby strengthening its profitability [6].

Core Viewpoint - Yingkang Life reported a slight decline in revenue but a significant increase in net profit, showcasing strong profitability and growth potential in a challenging private hospital industry [1][2][4] Financial Performance - Revenue for Q1 2025 decreased by 1.73% year-on-year to 409 million yuan, while net profit attributable to shareholders increased by 14.4% to 29.993 million yuan [1] - Non-recurring net profit surged by 25.8% year-on-year to 29.965 million yuan, indicating improved profit quality [2] Operational Efficiency - The company achieved a reduction in operating expenses, with the expense ratio decreasing by 2.9 percentage points [2] - The oncology revenue share rose to 31.9%, up 17 percentage points from the previous year, becoming a key growth driver [2] Strategic Initiatives - Yingkang Life announced the acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million yuan, aiming to enhance its regional medical center layout and expand oncology treatment capabilities [2] - The company has implemented an "AI + Medical" strategy since 2021, integrating AI across all aspects of diagnosis, management, and service [3] Technological Advancements - The launch of the "AI Innovation Application Platform" in April 2023, in collaboration with industry leaders, aims to enhance the entire service chain from disease screening to health management [3] - The company is transitioning from "tool empowerment" to "ecosystem reconstruction" in AI healthcare, providing a replicable model for intelligent transformation in the industry [3] Industry Positioning - Yingkang Life stands out in the private hospital sector, successfully navigating cost pressures and achieving profit growth while many smaller private hospitals face losses [3][4] - The company is positioned as a benchmark for transformation in the private hospital industry, leveraging AI, specialization, and external expansion to enhance quality alongside scale [4]